New York, NY -- (SBWIRE) -- 01/15/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Hovnanian Enterprises, Inc (NYSE:HOV), Synta Pharmaceuticals Corp (NASDAQ:SNTA), CytRx Corporation (NASDAQ:CYTR), ReneSola Ltd. (ADR) (NYSE:SOL)
Hovnanian Enterprises, Inc (NYSE:HOV) showed a volume of 2.33million shares by the end of last trade whereas the average volume of the stock remained 4.42 million shares. The stock opened the session at $6.15 but then moved to $6.17. At that price, the stock showed a positive performance of 0.49%. Hovnanian Enterprises, Inc. (Hovnanian) designs, constructs, markets, and sells single-family detached homes, attached townhomes and condominiums, mid-rise condominiums, urban infill and active adult homes in planned residential developments.
Will HOV Continue To Move Higher? Find Out Here
Synta Pharmaceuticals Corp (NASDAQ:SNTA) opened the session at $6.20 and closed the session at $6.41. The stock showed a positive performance of 3.72% in previous trading session. Traded with volume of 2.32 million shares in the prior session and the average volume of the stock remained 1.83 million shares. Synta Pharmaceuticals Corp. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing small molecule drugs to severe the medical conditions of the patients with cancer and inflammatory diseases.
For How Long SNTA will fight for Profitability? Read This Trend Analysis report
CytRx Corporation (NASDAQ:CYTR) opened the session at $7.94and closed the session at $7.34. The stock showed a negative performance of -1.74% in previous trading session. Traded with volume of 2.27 million shares in the prior session and the average volume of the stock remained 6.06 million shares. The beta of the stock remained 1.33. CytRx Corporation (CytRx) is a biopharmaceutical research and development company specializing in oncology. The Company's oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. INNO-206 is the Company's tumor-targeted doxorubicin conjugate.
Why Should Investors Buy CYTR After the Recent Fall? Just Go Here and Find Out
ReneSola Ltd. (ADR) (NYSE:SOL) the stock advanced 8.04% and finished the session at $4.03. Traded with volume of 2.26 million shares in the prior session and the average volume of the stock remained 4.21 million shares. The beta of the stock remained 3.17. ReneSola Ltd (ReneSola), incorporated on March 17, 2006, is a global manufacturer of solar wafers and producer of solar power products based in the People's Republic of China. ReneSola possess a global network of suppliers and customers that includes some of the global manufacturers of solar cells and modules.
Will SOL Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)